



May 8, 2020

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Ltd.,**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards successful close out of the inspection carried out by the Medicines and Healthcare products Regulatory Agency, the regulatory agency of the United Kingdom (UK), at the Company's three manufacturing units in Pithampur (India). The inspection for the three units at Pithampur (Unit I, Unit II and Unit III) was conducted in January 2020.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For LUPIN LIMITED

RAJVARDH
AN VISHNU
SATAM

Digitally signed by RAJVARDHAN VISHNU SATAM
DN: cn=RA, o=Personal,
email=rajvardhan.vishnu.satam@lupin.com,
c=IN, ou=Maharashtra,
2.5.4.20=c11988a7f61d9f29d973a003a4
d9394b253a3d9999a7a3a07f700053
75b7,
serialNumber=0f8a0d08b6796665c73
8a025f8a0b6475d19072a0b67a2000c4
2427776a, c=IN, ou=RAJVARDHAN VISHNU
SATAM
Date: 2020.05.08 15:25:09 +05'30'

R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)

Encl- : a/a.

Lupin's Pithampur Facilities Complete Successful UK MHRA Inspection

Mumbai, India, May 8, 2020: Pharma major Lupin Limited (Lupin) today announced the successful close out of the inspection carried out by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory agency of the United Kingdom (UK), at its three manufacturing units in Pithampur (India). The inspection for the three units at Pithampur (Unit I, Unit II and Unit III) was conducted in January 2020.

Commenting on the positive outcome, **Nilesh Gupta, Managing Director, Lupin** said, "We are committed to maintaining truly global quality standards at all our manufacturing facilities. The successful close out of the inspection at Pithampur, and release of the inspection report by UK MHRA further bolsters our confidence in our quality standards and manufacturing processes."

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/

Facebook: www.facebook.com/LupinWorld/

For further information or queries please contact –

Arvind Bothra

Head – Investor Relations and Corporate Communications

Email: arvindbothra@lupin.com

Tel: +91 22 6640 8237

Manjira Sharma

General Manager – Corporate Communications

Email: manjirasharma@lupin.com

Tel: +91 22 6640 2532